SCHEMBL17536667

SCHEMBL17536667

CCC(C)(C(=O)O)N(C)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
CYP2C19 P33261 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALDH1A1 P00352 5/20 0.44
GLA P06280 1/20 0.44
TSHR P16473 1/20 0.44
RIPK1 Q13546 3/20 0.44
TP53 P04637 1/20 0.43
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151140 1.00 KMT2A (0.44) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL3955413 0.82 HIF1A (0.46) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL2231434 0.76 KMT2A (0.46) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL6551664 0.76 CYP2C19 (0.38) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL17576276 0.74 MEN1 (0.38) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL18364997 0.74 MEN1 (0.38) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL11052172 0.74 ALDH1A1 (0.41) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL28682647 0.73 KMT2A (0.43) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL9229562 0.73 KMT2A (0.43) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4
SCHEMBL11687824 0.73 KMT2A (0.43) KMT2ACYP2C19SMN1; SMN2MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374707-A1 EXPRESSION SYSTEM AND NUCLEIC ACID-BASED PHARMACEUTICAL COMPOSITION COMPRISING SAME SML BIOPHARM CO, LTD. (KR) 2024-11-14 US disclosed
EP-4450628-A1 NUCLEIC ACID EXPRESSION PLATFORM WITH INCREASED EXPRESSION EFFICIENCY SML Biopharm Co., Ltd. (KR) 2024-10-23 EP disclosed
US-9943567-B2 Method for treating arthritis using IK factor or nucleic acid encoding IK factor Catholic University Industry Academic Cooperation Foundation (KR) 2018-04-17 US disclosed
CN-107427700-A Mineralising fluoride composition 墨尔本大学 2017-12-01 CN disclosed
US-9737588-B2 Method for treating arthritis using IK factor or nucleic acid encoding IK factor CELLINBIO CO., LTD (KR) 2017-08-22 US disclosed
US-20170209541-A1 METHOD FOR TREATING ARTHRITIS USING IK FACTOR OR NUCLEIC ACID ENCODING IK FACTOR CELLINBIO CO., LTD. (KR) 2017-07-27 US disclosed
US-20160058836-A1 IK FACTOR AND PHARMACEUTICAL USE OF NUCLEIC ACID ENCODING IK FACTOR CELLINBIO CO., LTD (KR) 2016-03-03 US disclosed
CN-104013963-A Dental mineralization UNIV MELBOURNE 2014-09-03 CN disclosed
CN-101217932-A tooth mineralization UNIV MELBOURNE (AU) 2008-07-09 CN disclosed